Research Reports | Market Assessment
May 2016

Respiratory Syncytial Virus (RSV) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for adults, contributing to the substantial unmet need for antivirals and vaccines. Several companies are developing therapeutic antivirals and prophylactic vaccines and antibodies for RSV. The anticipated launch of these agents is expected to transform the RSV space.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports